Patents by Inventor Daniel Fleischanderl
Daniel Fleischanderl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230017907Abstract: The present invention relates to a method for continuous recovering of a protein from a fluid, comprising precipitating the protein in the fluid and separating the precipitated protein from the fluid. The invention also provides an inclined plate settler that can be used for such continuous protein recovering.Type: ApplicationFiled: December 10, 2020Publication date: January 19, 2023Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Daniel FLEISCHANDERL, Christoph DATTENBOECK, Katerina PETRUSHEVSKA-SEEBACH, Thomas GATTERNIG, Martin PURTSCHER, Alois JUNGBAUER, Hannah ENGELMAIER, Nikolaus HAMMERSCHMIDT
-
Patent number: 10745672Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: GrantFiled: January 18, 2019Date of Patent: August 18, 2020Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
-
Publication number: 20190153400Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: ApplicationFiled: January 18, 2019Publication date: May 23, 2019Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
-
Patent number: 10221400Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: GrantFiled: April 12, 2017Date of Patent: March 5, 2019Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
-
Patent number: 10100099Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: GrantFiled: May 9, 2017Date of Patent: October 16, 2018Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl, Gregor Bramberger
-
Publication number: 20180051261Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: ApplicationFiled: April 12, 2017Publication date: February 22, 2018Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
-
Publication number: 20180044405Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: ApplicationFiled: May 9, 2017Publication date: February 15, 2018Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Daniel Fleischanderl, Gregor Bramberger
-
Patent number: 9650612Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: GrantFiled: October 10, 2013Date of Patent: May 16, 2017Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
-
Patent number: 9458222Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: GrantFiled: July 8, 2011Date of Patent: October 4, 2016Assignees: Baxalta Incorporated, Baxalta GmbHInventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl, Gregor Bramberger
-
Publication number: 20150056657Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: ApplicationFiled: September 3, 2014Publication date: February 26, 2015Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Daniel Fleischanderl, Gregor Bramberger
-
Publication number: 20140038264Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
-
Patent number: 8580554Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: GrantFiled: July 30, 2010Date of Patent: November 12, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl
-
Publication number: 20120034674Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.Type: ApplicationFiled: July 8, 2011Publication date: February 9, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl, Gregor Bramberger
-
Publication number: 20110086411Abstract: Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d?1, and a cell density of less than about 2×107 cell/mL.Type: ApplicationFiled: July 30, 2010Publication date: April 14, 2011Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Leopold Grillberger, Manfred Reiter, Daniel Fleischanderl